A closer reading
Keep the unanswered question in view.
Read one document at a time. “Documented” states what the cited record supports. “Unsupported inference to examine” identifies a tempting conclusion that the record does not establish. “Unresolved” keeps the remaining question visible instead of filling it with a guess.
These are fixed examples of reading public documents, not an assessment of your health or a recommendation about treatment. An unresolved claim is neither a demonstrated benefit nor proof of no effect. The reader collects no health answers and calculates no price, risk or medicine amount.
Provider statement read beside FDA guidance
A compounding claim and an actual medicine record
Documented
CoreAge explicitly advertises compounded tirzepatide. FDA explains that compounded drugs do not receive its premarket review for safety, effectiveness and quality. A state pharmacy-license record addresses the pharmacy’s licensing identity, rather than approval of every preparation it supplies.
Unsupported inference to examine
An unsupported inference would be that the ingredient name, a professional credential or a licensing badge proves the exact compounded medicine is an approved generic. None of those records establishes that conclusion.
Unresolved
The individual prescription’s full formulation, actual dispensing entity and relevant product explanation are not established by a general public offer. This reader has not verified a patient’s label or a particular pharmacy’s license.
Current public offer checked September 27, 2026
The two tirzepatide price documents
Documented
CoreAge’s dedicated tirzepatide page says from $199 per month. The shared offer labels tirzepatide at $129 monthly, while $79 belongs to a separate semaglutide card. The shared-page footer bases starting prices on a twelve-month plan paid in full and defers order-specific billing and renewal details to checkout.
Unsupported inference to examine
An unsupported inference would be that all three figures are tirzepatide prices, or that the displayed $129 means a customer initially pays only that amount. The product labels and prepayment qualification do not support either shortcut.
Unresolved
The reviewed public records do not explain why the two tirzepatide figures differ or establish an individual final charge. No checkout, payment, cancellation or refund was tested. A selected quote would need to reconcile the documents and name its full terms.
Read the original records
CoreAge Rx: Tirzepatide Microdosing Therapy →CoreAge Rx: Shared microdose offer and qualifications →FDA safety-report information
An adverse-event report total
Documented
FDA lists more than 730 reports associated with compounded tirzepatide through May 31, 2026. Its AEMS dashboard explanation, formerly FAERS, states that reports can be duplicate, incomplete and unverified, and cannot establish an event’s incidence or prove that a medicine caused it.
Unsupported inference to examine
An unsupported inference would be that this total measures the chance of harm from one provider’s microdosing program. A smaller or absent count also does not demonstrate that a preparation is safer.
Unresolved
The total does not supply the number of all exposed patients, a complete account of unreported events or the cause of every submitted event. These records can support safety investigation without deciding an individual symptom’s cause or recommending a medicine change.
SURMOUNT-4 primary paper, published 2023
A continuation trial and a maintenance advertisement
Documented
SURMOUNT-4 enrolled adults with obesity or qualifying overweight without diabetes; qualifying overweight required a weight-related complication. After an initial tirzepatide treatment period, 670 participants were randomized to continued treatment or placebo. The study found further average weight reduction with continuation and substantial regain after withdrawal during the randomized period.
Unsupported inference to examine
An unsupported inference would be that the trial proved the same outcomes for an advertised lower-amount compounded maintenance program. That particular intervention was not a randomized arm, and the post-lead-in participants were a selected population.
Unresolved
A different proposal needs evidence that matches its preparation, treatment approach, participants and intended outcome. The trial supplies neither an individual continuation or stopping rule nor a result for an exact commercial microdosing service.